Targeted therapy for metastatic renal cell carcinoma Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Carcinoma, Renal Cell
  • Enzyme Inhibitors
  • Kidney Neoplasms
  • Protein-Tyrosine Kinases

abstract

  • Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab. The results of phase III studies will determine the role of these agents in metastatic RCC.

publication date

  • March 13, 2006

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC2361211

Digital Object Identifier (DOI)

  • 10.1038/sj.bjc.6602978

PubMed ID

  • 16465192

Additional Document Info

start page

  • 614

end page

  • 9

volume

  • 94

number

  • 5